Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Purple Biotech announced new preclinical data for its lead asset IM1240, showing that all seven tested patient-derived tumor samples responded to treatment, including those resistant to PD-1 and chemotherapy. Data generated at Mount Sinai demonstrated that the NKG2A arm significantly enhances anti-tumor activity and induces tertiary lymphoid structures in NSCLC models, improving the therapeutic index.
Key figures
- Drug Name
- IM1240
- Phase Of Trial
- Preclinical
- Response rate
- 100%
- Samples tested
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.